Jun. 4 at 2:21 PM
$IMRX $RVMD
Breakthrough efficacy:
At ASCO, daraxonrasib nearly doubled overall survival in metastatic pancreatic cancer (~13.2 months) — a true scientific milestone.
But safety matters:
NEJM data show 85.5% of patients developed rash (any grade).
33% experienced grade ≥3 rash, indicating substantial toxicity.
Patient experience is significant:
For patients with limited life expectancy (~13 months), these side effects are not minor — they meaningfully shape quality of life.
Trial vs. real-world reality:
Trial participants were highly selected.
In routine practice, adverse event rates are likely to be equal or higher.
Early physician feedback suggests hesitancy in enrolling patients in ongoing 1L studies due to tolerability concerns.
Implication for first-line (1L) treatment:
While efficacy is compelling, tolerability will influence adoption.
A first-line option with comparable efficacy but without serious adverse events (SAEs) would represent a clear clinical advantage.
